Management and Advisors

Management and Advisors

  • Stephanie Unwin, LLB, BEcon, CEO
  • Robert Hayes, PhD, CSO
  • Kevin Hart, B.Com, FCA
  • Judy Lieberman, MD, PhD
  • Stephen Doberstein, B.S.Ch.E, PhD
  • Shohei Koide, B.S, M.S, PhD
  • Paul Watt, BSc(Hons), PhD


Stephanie Unwin, LLB, BEcon | Chief Executive Officer

Stephanie Unwin brings extensive senior executive and commercial experience to PYC. Since becoming an executive general manager in 2011, Stephanie has held positions of increasing responsibility, including Head of Strategy and Innovation; Chief Transformation Officer; and General Manager of both Commercial and Retail Business Units within the $3bn electricity utility.

Stephanie’s experiences range across operational and commercial topics, including managing the retail P&L and an internal team of over 150 people, presiding over multiple complex commercial transactions, including the merger of Verve Energy and Synergy. She also has substantial experience as a company Director with over 15 years of Board engagements across both ASX and TSX including a Non-Executive Director role overseeing the growth of Alacer Gold from a junior ASX listed entity to a $2bn dual listed company at its height.

Robert Hayes, PhD | Chief Scientific Officer

Robert Hayes is the former Head of Biologics at Amgen and Vice President at Janssen Pharmaceuticals, a Johnson and Johnson company, where he was the Head of Centyrex, a biotechnology company dedicated towards developing novel proteins as therapeutics with transformational properties. During this time, Centyrex entered into a collaboration with Phylogica to understand the ability to use Phylomers to deliver therapeutic proteins into cells.

Rob brings over 18 years of experience in biotechnology research and development to Phylogica. In this newly created role, he will lead all aspects of discovery research at Phylogica. At Amgen, he was responsible for leadership, operational and strategic management of all aspects of biologics preclinical discovery and the biotherapeutics pipeline, including bioreagent generation, large molecule identification, optimization and transition to the manufacturing arm. At Centyrex, Rob established programs resulting in multiple strategic alliances with partners, built a strong proprietary pipeline, and moved multiple product candidates from concept to pre-IND stages in both oncology and immunology. Before that, Rob was Director of Antibody Engineering at Xencor, an antibody and protein engineering and development company.

Kevin Hart, B.Com, FCA | Company Secretary

Kevin Hart is a Chartered Accountant and has over 30 years experience in accounting, management and administration of public listed entitles. He is currently a partner in an advisory firm, Endeavour Corporate, which specialises in the provision of company secretarial and accounting services to ASX listed entities.

Kevin holds a Bachelor of Commerce degree from the University of Western Australia and is a Fellow of the Institute of Chartered Accountants.

Judy Lieberman, MD, Ph.D | Scientific Advisor

Judy Lieberman, MD, Ph.D, holds a Chair in Cellular and Molecular Medicine at Boston Children’s Hospital, is Professor of Pediatrics at Harvard Medical School and is Chair of the Executive Committee of Immunology at Harvard Medical School. She earned a Ph.D. in theoretical physics from Rockefeller University and worked as a theoretical physicist at the Institute for Advanced Study in Princeton and Fermilab, received an M.D. from Harvard and MIT, did a postdoctoral fellowship in immunology in the Cancer Center at MIT and worked as hematologist/oncologist at Tufts Medical Center.

Her laboratory has been in the forefront of developing RNAi-based therapeutics and using RNAi for genome-wide screening. They were the first to show that siRNAs could be used to treat disease in vivo and to develop cell-targeted RNAs.

The Lieberman laboratory has developed strategies for cell-specific siRNAs that knockdown gene expression in vivo in T lymphocytes and cancer cells. They also investigate the role of microRNAs in regulating cell differentiation and cancer. This laboratory also studies cytotoxic T lymphocytes and their role in immune protection from infection and cancer.

Dr. Lieberman served as the Chair of the Medical Sciences section and on the Council of the American Association for the Advancement of Sciences. She has received numerous awards for her research on vaccines, immunology and cancer. She is a member of the American Academy of Arts and Sciences.

Stephen Doberstein, B.S.Ch.E, Ph.D | Scientific Advisor

Steve Doberstein joined Nektar Therapeutics in January 2010 as Senior Vice President and Chief Scientific Officer to lead all aspects of the company’s drug discovery research.

Dr. Doberstein has over 17 years of experience in biotechnology research and development, and prior to joining Nektar Therapeutics was Vice President of Research at XOMA (NASDAQ:XOMA) where he was responsible for directing the discovery and development of their drug candidates, including antibody discovery and support of clinical development through non-clinical safety, translational medicine and

Dr. Doberstein also served as Vice President, Research at Five Prime Therapeutics (NASDAQ:FPRX), a protein and antibody discovery and development company where he built and led a high performance discovery research and process development group.
While at Five Prime, he established programs resulting in multiple strategic alliances with pharmaceutical partners, built a strong proprietary pipeline, and moved multiple product candidates from concept to pre-IND stages in diabetes, oncology, rheumatoid arthritis and osteoarthritis. Prior to working with Five Prime, Dr. Doberstein was Vice President, Research at Xencor (NASDAQ:XNCR), an antibody and protein engineering and development company. At Xencor, he was instrumental in advancing its protein platform technologies and preclinical product candidates.

Dr. Doberstein received his Ph.D. in Biochemistry, Cell and Molecular Biology from the Johns Hopkins University School of Medicine, and completed his postdoctoral work at UC Berkeley. Earlier in his career, Dr. Doberstein held a variety of engineering roles at DuPont after receiving his B.S.Ch.E. degree in Chemical Engineering from the University of Delaware.

Shohei Koide, B.S, M.S, Ph.D | Scientific Advisor

Dr. Koide is Professor of Biologics Design in the Department of Biochemistry and Molecular Pharmacology at New York University School of Medicine, and Director of the Cancer Biologics platform at the Perlmutter Cancer Center at NYU Langone Health. Prior to joining NYU, he was Professor of Biochemistry and Molecular Biology at University of Chicago from 2002 to 2016. In addition, he served as a scientific co-director of the Chicago Biomedical Consortium, and also is a fellow of the American Association for the Advancement of Science.

Dr. Koide has been actively engaged in protein engineering and design over the last two decades. He is best known for his work in the development of “monobodies,” designer binding proteins with antibody-like properties and for his contribution to the development of synthetic antibody technologies. His research seamlessly integrates rational design, directed evolution, structural biology and cell biology to design highly functional but still simple protein molecules. He has applied such synthetic proteins as powerful tools for addressing fundamental challenges in biology, medicine and chemistry. His team has developed monobody inhibitors to “undruggable” targets, such as RAS and protein phosphatases, which have inspired novel therapeutic strategies.

Dr. Koide earned his undergraduate B.S., graduate M.S. and post-graduate Ph.D. degrees at the University of Tokyo. He subsequently was a Human Frontier Science Program post-doctoral fellow at The Scripps Research Institute in La Jolla, CA and started his independent career as Assistant Professor of Biochemistry and Biophysics at the University of Rochester School of Medicine and Dentistry.

Dr. Koide has published more than 100 peer-reviewed articles in top-tier journals, including Nature, Cell, Science, Molecular Cell, Nature Methods and PNAS. His research has continuously been funded through the U.S. National Institutes of Health, and he holds several U.S. and overseas patents on findings resulting from his research.

Paul Watt, BSc(Hons), PhD | Scientific Advisor

Adjunct Professor Watt is the founder of Phylogica and continues to provide strategic scientific services to the company as a Scientific Advisor.

Professor Watt has published more than 55 peer reviewed papers, and has filed 24 patent applications many of which are granted in the US and Europe. Specialising in drug discovery biotechnology and molecular biology, he has attracted over A$10 million in research funding from Australia and the United States to develop the technology underpinning Phylogica.

Previously Professor Watt founded InfaMed Ltd, now owned by Avita Medical Ltd, which commercialised an FDA-approved / CE-marked paediatric drug delivery device that he invented, which has been marketed internationally. He was appointed Adjunct Professor at the School of Paediatrics and Child Health at the University of Western Australia and is now Director of Research Services and Innovation at the Telethon Kids Institute, where Phylogica’s discovery research is carried out.

Professor Watt carried out postdoctoral research in yeast genetics at Harvard and Oxford Universities, where he discovered and characterised proteins involved in maintaining genome stability. He has a doctorate in Molecular Biology from Oxford University and BSc (Hons) from the University of Western Australia.